Adjuvant chemotherapy with S-1 plus oxaliplatin improves survival of patients with gastric cancer after D2 gastrectomy: A multicenter propensity score-matched study

Table 2 Clinicopathologic features of the study population in adjuvant S-1 plus oxaliplatin group and adjuvant capecitabine plus oxaliplatin group before and after propensity score-matching n (%)

Variable	Before PSM (n = 184)			After PSM (n = 114)
	Adjuvant SOX(n = 124)	Adjuvant XELOX(n = 60)	P value	Adjuvant SOX(n = 57)	Adjuvant XELOX(n = 57)	P value
Age at diagnosis (yr)			0.322			0.848
≤ 60	69 (55.65)	38 (63.33)		34 (59.65)	35 (61.40)
> 60	55 (44.35)	22 (36.67)		23 (40.35)	22 (38.60)
Gender			1			0.404
Female	31 (25.00)	15 (25.00)		18 (31.58)	14 (24.56)
Male	93 (75.00)	45 (75.00)		39 (68.42)	43 (75.44)
Tumor location			0.567			1
None-Cardia cancer	88 (70.97)	45 (75.00)		42 (73.68)	42 (73.68)
Cardia cancer	36 (29.03)	15 (25.00)		15 (26.32)	15 (26.32)
Tumor grade			0.521			0.233
Moderate to well	4 (3.23)	1 (1.67)		4 (7.02)	1 (1.75)
Moderate	21 (16.94)	14 (23.33)		13 (22.81)	12 (21.05)
Poor to moderate	97 (78.23)	45 (75.00)		38 (66.67)	44 (77.19)
Early cancer or not reported	2 (1.61)	0 (0.00)		2 (3.51)	0 (0.00)
Pathological stage			0.038			0.708
IB1	8 (6.45)	11 (18.33)		7 (12.28)	9 (15.79)
II	29 (23.39)	10 (16.67)		12 (21.05)	9 (15.79)
III	87 (70.16)	39 (65.00)		38 (66.67)	39 (68.42)
Lymphatic and venous invasion			0.929			0.839
No	86 (69.35)	42 (70.00)		39 (68.42)	40 (70.18)
Yes	38 (30.65)	18 (30.00)		18 (31.58)	17 (29.82)
Perineural invasion			0.102			1
No	107 (86.29)	46 (76.67)		46 (80.70)	46 (80.70)
Yes	17 (13.71)	14 (23.33)		11 (19.30)	11 (19.30)

¹Patients of stage IB (pT2N0M0) without high-risk features including poorly differentiated or higher grade cancer, lymphovascular invasion, neural invasion, or < 50 years of age were not included. SOX: S-1 plus oxaliplatin; XELOX: Capecitabine plus oxaliplatin; PSM: Propensity score-matching.